Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth

Rhea-AI Summary

Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth. The company converted approximately $9 million of short and long-term liabilities into equity and extended note maturities to two and three years, strengthening liquidity and aligning with long-term investors.

The company said no future equity lines or forward-priced agreements are anticipated; additional transaction details are available in its Form 8-K filings.

Positive

• $36.5M institutional financing secured
• Approximately $9M liabilities converted into equity
• Extended note maturities to 2–3 years
• ATM equity program terminated; no future equity lines anticipated

Negative

• Conversion into equity may cause shareholder dilution
• Press release omits pricing and specific transaction terms

Market Reaction

-8.95% $1.73 22.6x vol

15m delay 8 alerts

-8.95% Since News

+3.7% Peak Tracked

-36.4% Trough Tracked

$1.73 Last Price

$1.69 $2.00 Day Range

-$312K Valuation Impact

$3M Market Cap

22.6x Rel. Volume

Following this news, VTAK has declined 8.95%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.7% during the session. Argus tracked a trough of -36.4% from its starting point during tracking. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.73. This price movement has removed approximately $312K from the company's valuation. Trading volume is exceptionally heavy at 22.6x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Strategic financing size: $36.5 million Liabilities converted: approximately $9 million Private placement gross proceeds: $2,177,759.00 +5 more

8 metrics

Strategic financing size $36.5 million Institutional financing capacity referenced in Feb 12, 2026 release

Liabilities converted approximately $9 million Additional short and long-term liabilities on 9/30/25 balance sheet converted to equity

Private placement gross proceeds $2,177,759.00 Initial closing from Feb 6, 2026 8‑K private placement

Optional Series C-4 capacity $39,233,333 Investor option to buy additional Series C-4 preferred per Feb 6, 2026 8‑K

Fly Flyte stake value $5.25 million Value of 19.98% Fly Flyte, Inc. stake in Feb 6, 2026 8‑K

Q3 2025 revenue $226,000 Quarter ended September 30, 2025 from 10‑Q

Q3 2025 net loss $2.251 million Net loss attributable to company in Q3 2025 10‑Q

Cash balance $1.075 million Cash and cash equivalents as of September 30, 2025 per 10‑Q

Market Reality Check

Price: $1.90 Vol: Volume 24,503 is in line ...

normal vol

$1.90 Last Close

Volume Volume 24,503 is in line with the 20-day average of 24,243 (relative volume 1.01x). normal

Technical Shares trade below the 200-day moving average at 3.21, despite balance sheet strengthening news.

Peers on Argus

VTAK was down 2.56% with light, average-like volume. Several listed medical devi...

VTAK was down 2.56% with light, average-like volume. Several listed medical device peers (NUWE, BBLG, BJDX, VERO, NAOV) also showed single- to low-double-digit declines, but no peers appeared in the momentum scanner, and the move is flagged as stock-specific rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Product visibility	Positive	-4.8%	LockeT device featured in live procedural cases at a major conference.
Feb 04	Commercial update	Positive	+1.6%	Expanded hospital approvals and highest January revenue for LockeT.
Jan 22	International expansion	Positive	+10.4%	First LockeT purchase order in Germany, entering a large EP devices market.
Jan 20	Global footprint	Positive	-1.9%	New VIVO order in Slovenia, expanding commercial reach to 15 countries.
Dec 18	European expansion	Positive	+0.9%	Multi‑year LockeT commitment at a major Irish EP center, eighth EU country.

Pattern Detected

Recent news has been consistently positive on commercialization and expansion, but price reactions were mixed, with 3 aligned and 2 divergence outcomes.

Recent Company History

Over the last few months, VTAK has focused on commercial expansion of its LockeT and VIVO platforms, including new purchase orders in Germany and Ireland and growth to 15 countries. These updates often highlighted workflow benefits and international adoption, with some days seeing double‑digit gains and others modest declines. Against that backdrop, the new announcement of up to $36.5 million in institutional financing and conversion of about $9 million of liabilities into equity extends the prior balance sheet work disclosed in recent 8‑K filings and follows ongoing efforts to address going‑concern risks noted in the Q3 2025 10‑Q.

Market Pulse Summary

The stock is down -8.9% following this news. A negative reaction despite balance sheet strengthening...

Analysis

The stock is down -8.9% following this news. A negative reaction despite balance sheet strengthening would fit VTAK’s history of mixed responses to positive news. The financing provides access to up to $36.5 million and converts roughly $9 million of liabilities into equity following prior proceeds of $2,177,759.00, but investors may focus on ongoing losses such as the Q3 2025 net loss of $2.251 million. Concerns around prior going‑concern language and potential dilution could weigh on sentiment even as near‑term liquidity improves.

Key Terms

at-the-market equity offering program, form 8-k, schedule 13g, convertible preferred stock, +3 more

7 terms

at-the-market equity offering program financial

"agreed to the termination of its at-the-market (“ATM”) equity offering program"

A program that lets a company sell newly issued shares directly into the open market at whatever the current trading price is, usually through a broker, and do so gradually over time instead of all at once. Investors care because it can dilute existing ownership and put steady selling pressure on the stock price, while giving the company a flexible, on-demand way to raise cash — like adding small amounts of water to a pool rather than dumping in a bucket.

form 8-k regulatory

"Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

schedule 13g regulatory

"Catheter Precision, Inc. (VTAK) received a Schedule 13G filing"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

convertible preferred stock financial

"multiple new series of convertible preferred stock to raise capital"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

registration rights agreement regulatory

"A registration rights agreement requires Catheter Precision to register resales"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

reverse stock split financial

"A 1‑for‑19 reverse stock split became effective on August 15, 2025"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

going concern financial

"Management states there is substantial doubt about the ability to continue as a going concern"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

AI-generated analysis. Not financial advice.

VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program

Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation

FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market (“ATM”) equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth.

Key Highlights:

• ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated.
• Strategic institutional capital secured to fund expansion
• Balance sheet and liquidity significantly strengthened
• The company’s short-term notes have been converted to long term by extending maturities out to two and three years
• Additional short and long-term liabilities of approximately $9 million on the 9/30/25 balance sheet are being converted into equity
  
  

Executive Commentary
“This financing and balance sheet restructuring strengthens our financial position and also reinforces institutional investor confidence in our strategy,” said David Jenkins, CEO and Chairman of VTAK.

Jenkins added, “By eliminating legacy financing overhang and aligning ourselves with long-term institutional partners, we’ve enhanced our ability to execute with speed, discipline, and focus.”

Jenkins concluded, “We now move forward from a position of financial strength, supported by capital, stability, and strategic alignment to drive meaningful shareholder value through disciplined growth.”

Capital Strategy Update
This strategic institutional investment provides the Company with financial flexibility to:

• Advance key growth initiatives
• Scale multiple business opportunities
• Expand market presence and execution capabilities
  
  

Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026, and February 12th for additional details regarding the transaction.

About Catheter Precision
Catheter Precision is a U.S.-based medical device company developing innovative solutions to improve the treatment of cardiac arrhythmias. The Company is committed to bringing new technologies to market through physician collaboration and continued product innovation.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company’s SEC filings, available at www.sec.gov. The Company undertakes no obligation to update these statements except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What financing did Catheter Precision (VTAK) announce on February 12, 2026?

Catheter Precision announced a strategic institutional financing of up to $36.5 million. According to the company, the funding supports growth initiatives and strengthens liquidity while aligning with long-term institutional investors.

How did the February 12, 2026 financing affect VTAK's balance sheet?

The financing strengthened VTAK's balance sheet by converting liabilities into equity and extending notes. According to the company, about $9 million of short and long-term liabilities were converted to equity and maturities extended to two and three years.

What change did Catheter Precision make to its ATM program on February 12, 2026?

Catheter Precision terminated its at-the-market (ATM) equity offering program and expects no future equity lines. According to the company, this removes legacy financing overhang and aligns capital with long-term institutional partners.

Will the VTAK financing cause shareholder dilution?

The transaction includes conversion of liabilities into equity, which can dilute existing shareholders. According to the company, approximately $9 million of liabilities were converted to equity, though exact dilution percentages were not disclosed.

Where can investors find more details about the VTAK financing transaction?

Investors should review the company's Form 8-K filings filed February 6 and February 12, 2026 for details. According to the company, those filings contain additional transaction terms and disclosures not included in the press release.